In conclusion, our findings demonstrate that SGLT2 inhibition exhibits significant therapeutic potential in AD through AMPK‐induced enhancement of microglial phagocytosis of Aβ, reduction of neuroinflammation, and improvement of synaptic function. Here, SLC5A2 is linked to Alzheimer disease.